Cancer Research and Biotechnology AG

Cancer Research and Biotechnology AG is a Swiss biopharmaceutical company focused on developing novel oncology treatments that address cancer as a metabolic disease. The company specializes in identifying and reversing the mitochondrial dysfunctions and cellular processes that drive tumor progression. Their lead therapeutic candidate, CRB091, is a small-molecule drug designed to selectively eradicate cancer cells while protecting healthy tissue. This approach aims to provide a more tolerable alternative to conventional therapies that often result in significant patient toxicity.

By targeting metabolic engines within cells, the company is working to improve treatment options for aggressive and difficult-to-treat cancers, including metastatic melanoma, triple-negative breast cancer, and colorectal cancer. Through preclinical research, the company has documented significant tumor volume reduction and efficacy in human cancer cell lines. The organization is currently advancing its pipeline through accelerated regulatory pathways, with efforts focused on reaching first-in-human clinical trials to address unmet medical needs in oncology.